For clinically important hypotension resulting primarily from vasodilation in the…. ANDA 210665, held by Fresenius Kabi USA. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 210665 (Phenylephrine Hydrochloride), held by Fresenius Kabi USA, was first approved by FDA on Jan 29, 2019, with 0 approved supplements and 0 published complete response letters.
Phenylephrine Hydrochloride Injection 10 mg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phenylephrine Hydrochloride10MG/ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters